It was reported via journal article that patient complications occurred.A retrospective single center study was performed with 38 child-pugh a patients with advanced/metastatic hcc.In sum, 34 received sorafenib, followed after 4 weeks by 90y gms.Analysis of safety and survival outcomes was performed to assess adverse events, median progression-free survival, and overall survival.The y-90 therasphere dose vials were referenced within the study.Grade iii-iv adverse events from the combination of sorafenib and therasphere comprised fatigue, diarrhea, nausea, vomiting, hypertension, thrombocytopenia, hyperbilirubinemia, proteinuria, hyponatremia, and elevated alanine or aspartate aminotransferase.
|
Journal article: kaseb, ahmed omar, et al."a prospective phase ii study of safety and efficacy of sorafenib followed by 90y glass microspheres for patients with advanced or metastatic hepatocellular carcinoma." journal of hepatocellular carcinoma 8 (2021): 1129.Date of event = month of article submission.
|